Clinical trials: Acute Uncomplicated Diverticulitis

Uncomplicated Diverticulitis

Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. Placebo in Acute Uncomplicated Diverticulitis

• Completed
• Age: 18 to 80 years
• Phase 2

The purpose of the trial is to compare the efficacy of Rifamycin SV-MMX® 400 mg b.i.d. vs. Rifamycin SV-MMX® 600 mg t.i.d. vs. placebo in patients with acute uncomplicated diverticulitis.

Trial name

NCT01847664

Testing

Rifamycin SV-MMX® 400 mg b.i.d., Rifamycin SV-MMX® 600 mg t.i.d.

Where

Germany

Volunteers

204 people

Sponsor

Dr. Falk Pharma GmbH